PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18624866-9	2008	CONCLUSIONS: In children and adolescents with a history of mild or moderate AD but free/almost free of signs or symptoms of the disease, early treatment of subsequent AD exacerbations with pimecrolimus cream 1% prevented progression to flares requiring TCS, leading to fewer unscheduled visits and reducing corticosteroid exposure.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	253-256	GTF2I repeat domain containing 1	Homo sapiens	202-209	
17935515-2	2007	OBJECTIVES: This study was designed to assess the efficacy and safety of pimecrolimus cream 1% in patients with AD of the face and neck who are either dependent on, or intolerant of, TCS.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	183-186	GTF2I repeat domain containing 1	Homo sapiens	86-93	
17935515-14	2007	CONCLUSION: Pimecrolimus cream 1% is effective in patients with head and neck dermatitis intolerant of, or dependent on, TCS.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	121-124	GTF2I repeat domain containing 1	Homo sapiens	25-32	
19067708-3	2009	OBJECTIVES: The primary study objective was to determine the efficacy of pimecrolimus cream 1% in children with mild-moderate facial AD dependent on/intolerant of TCS.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	163-166	GTF2I repeat domain containing 1	Homo sapiens	86-93	
19067708-12	2009	CONCLUSIONS: In children with facial dermatitis intolerant of/dependent on TCS, pimecrolimus cream 1% effectively controls eczema and pruritus and is well tolerated.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	75-78	GTF2I repeat domain containing 1	Homo sapiens	93-100	
18341665-10	2008	In comparison with vehicle cream, pimecrolimus cream 1% reduced the mean number of flares requiring TCS use from 1.39 to 0.97 (P=0.0014).	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	100-103	GTF2I repeat domain containing 1	Homo sapiens	47-54	
18341665-12	2008	CONCLUSIONS: In adults with a history of mild or moderate AD but free of active skin lesions, intervention with pimecrolimus cream 1% at the first signs and/or symptoms of a subsequent recurrence reduces the number of flares requiring TCS use and decreases the number of disease-related office visits.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	235-238	GTF2I repeat domain containing 1	Homo sapiens	125-132